Pfizer (PFE) Return on Capital Employed (2009 - 2026)
Pfizer (PFE) posted quarterly Return on Capital Employed of 25.44% for Q1 2026, down 3937.0% year-over-year from 0.66% in Q1 2025, and up 2.17% quarter-over-quarter from 26.0% in Q4 2025.
Pfizer (PFE) Return on Capital Employed (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Return on Capital Employed for 18 consecutive years, with 25.44% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3937.0% year-over-year to 25.44%; the TTM figure through Mar 2026 stood at 25.44% (down 3937.0% YoY), while the FY2025 annual figure was 18.51%, up 309.0% from the prior year.
- Return on Capital Employed improved to 25.44% in Q1 2026 per PFE's latest filing, from 26.0% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.57% in Q3 2022 and bottomed at 26.0% in Q4 2025.
- Historically, Return on Capital Employed has averaged 3.14% across 5 years, with a median of 6.03% in 2023.
- Annual changes were most pronounced in 2025 — Return on Capital Employed jumped 2583 bps — and 2026, when it slumped 3937 bps.
- Pfizer's Return on Capital Employed stood at 35.57% in 2022, then sank by 146 bps to 16.31% in 2023, then jumped by 118 bps to 2.95% in 2024, then sank by 980 bps to 26.0% in 2025, then grew by 2 bps to 25.44% in 2026.
- Business Quant data shows PFE's Return on Capital Employed at 25.44% in Q1 2026, 26.0% in Q4 2025, and 10.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 647.98 Bn | 627.22 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 466.45 Bn | 459.88 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 372.04 Bn | 364.90 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 299.31 Bn | 291.62 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 256.25 Bn | 251.35 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 235.50 Bn | 221.52 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.26 Bn | 147.56 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 104.79 Bn | 100.62 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 54.62 Bn | 47.24 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 11.86% |
| Mar 29, 2026 | -25.44% |
| Dec 31, 2025 | -26.00% |
| Sep 28, 2025 | 10.63% |
| Jun 29, 2025 | 6.77% |
| Mar 30, 2025 | 13.93% |
| Sep 29, 2024 | 2.95% |
| Jun 30, 2024 | -8.52% |
| Mar 31, 2024 | -11.90% |
| Dec 31, 2023 | -16.31% |
| Jul 2, 2023 | 6.03% |
| Apr 2, 2023 | 22.94% |
| Jul 3, 2022 | 35.57% |
| Apr 3, 2022 | 30.10% |
| Oct 3, 2021 | 41.43% |
| Jul 4, 2021 | 19.77% |
| Apr 4, 2021 | 17.40% |
| Sep 27, 2020 | 8.91% |
| Jun 28, 2020 | 2.49% |
| Mar 29, 2020 | 4.50% |